AbbVie Inc (ABBV)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$2.47
-13.64%
HEALTHCARE · Cap: $18.94M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 303560% more annual revenue ($62.82B vs $20.69M). ABBV leads profitability with a 5.8% profit margin vs 5.8%. ZJYL trades at a lower P/E of 12.1x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ZJYL
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for ZJYL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.7% — below average capital efficiency
5.8% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ZJYL
The strongest argument for ZJYL centers on Price/Book, P/E Ratio.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
ZJYL carries more volatility with a beta of 7.23 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 36/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?